Corporate Symposia Schedule
Wednesday, May 1
11:30 am – 12:45 pm
Emapalumab – A New Treatment for Patients with Primary HLH (pHLH)
Michael B. Jordan, MD; Professor Franco Locatelli
This non-CME symposium. This session will highlight the burden patients with pHLH experience as well as the clinical study data of the newly approved therapy emapalumab. The session format will be an open forum to ensure engagement. Leading physicians in the treatment of pHLH, will host the presentation and will be available to answer any questions that may arise during the session.
This non-CME symposium is supported by Sobi, Inc.
Thursday, May 2
HEMLIBRA: A New Approach to Prophylaxis in Hemophilia A
Guy Young, MD
This non-CME symposium. A panel discussion covering HEMLIBRA clinical trial data, novel mechanism of action, dosing and administration, and prescribing information. Unique perspectives from patients/caregivers will be shared.
This non-CME symposium is supported by Genentech